| Betulinol derivatives as anti-cancer agents -> Monitor Keywords |
|
|
 
Betulinol derivatives as anti-cancer agentsRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Cyclopentanohydrophenanthrene Ring System DoaiBetulinol derivatives as anti-cancer agents description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060154903, Betulinol derivatives as anti-cancer agents. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] This application claims the priority benefit of U.S. Provisional Patent Application Ser. No. 60/609,080, filed Sep. 10, 2004, U.S. Provisional Patent Application Ser. No. 60/630,103, filed Nov. 22, 2004, and U.S. Provisional Patent Application Ser. No. 60/630,150, filed Nov. 22, 2004, which are hereby incorporated by reference in their entirety. FIELD OF THE INVENTION [0002] The present invention relates generally to methods of treating cancer as well as conjugated and immunoconjugated betulinol derivative compounds and methods of making them. BACKGROUND OF THE INVENTION [0003] Development of early diagnostic methods as well as drugs to treat cancer remains one of the most challenging demands on medical research. There is also an increasing interest in tumor-associated antigens as potential targets for the diagnosis and as targets for site directed drug delivery of cancer chemotherapeutic agents. Use of immunoconjugates of drugs with antibodies directed to tumor associated antigens would achieve higher bioavailability and therapeutic index of the drug, as well as diminished adverse side affects usually associated with chemotherapy. [0004] Anti-tumor affect of pentacyclical styrene (terpenoids) has already been mentioned in the literature (Agnihotri et al., Indian J. Pharm. Sci. 2:42 (1987); Maurua et al., Fitotherapia 60:468-469 (1989); Pisha et al., Nature Medicine 1:1046 (1995); and Ukkonen et al., Birch Bark Extractive Kemia Kemi 6:217 (1979). Other lupan-row derivatives of betulinol, namely, betulinic acid, betulonic acid, betulin aldehyde, and betulon aldehyde are emerging as a new class of anticancer agents. Pentacyclic styrenes show anti-tumor activity against carcinosarcoma growth (Sheth et al., J. Pharm. Sci. 61:1819 (1972)), Epstein-Barr virus in lymphoblastoid Raji cells (Liu et al., Acta Bot. Sin. 29:84-87 (1987); Konoshima et al., J. Nat. Prod. 50:1166-1170 (1987)), and nasopharynx carcinosarcoma in vitro (Miles et al., J. Pharm. Sci. 63:613 (1974)). Pentacyclic styrenes also show anti-tumor activity against MCF-7 breast adenoma and P-333 leukemia in vitro (Kahlos Acta Pharm. Feun. 96:33 (1987)). Betulinic acid showed cytotoxic activity against carcinoma cell line CO-115 of the large intestine (LD 50=0.375 mg/ml) (Ukkonen et al., Birch Bark Extractive Kemia Kemi 6:217 (1979)). The anti-cancer activity of the terpenoids was also confirmed in vivo against Walker-256 carcinosarcoma, as tested on mice and rats. It has been suggested that betulinic acid may be the main anti-tumor agent in the mixture of terpenoids (Tomas et al., Planta Medicina 54:266-267 (1988); Jumal et al., India Chem. Soc. 61:92-93 (1964)). Betulinol and its derivatives have shown minimal adverse effect on normally proliferating cells and non-target tissues (Fulda et al., Neoplasia 7:162-170 (2005)). [0005] Betulinol derivatives in general, and betulonic acid in particular, are soluble in a number or organic solvents such as ethanol and DMSO. However, betulonic acid and the known betulinol derivatives are generally insoluble in aqueous environment or other pharmaceutically acceptable solvents. Good solubility in an aqueous environment is an important property for a pharmaceutical agent. Absent this property, administration of the pharmaceutical agent to mammals can be difficult and biologically activity in such mammals (including humans) may be impeded or entirely absent. Due to their limited solubility in aqueous solutions, the use of terpenoids such as betulinol and it derivatives as pharmaceuticals has been limited. To be effective as a pharmaceutical agent, especially for oral ingestion, water soluble betulinol derivatives would be desirable. [0006] The present invention is directed to overcoming these and other limitations in the art. SUMMARY OF THE INVENTION [0007] One aspect of the present invention relates to a method of treating a cancer selected from the group consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a subject having the cancer a compound of Formula I where [0008] R.sup.1 is selected from the group consisting of --CH.sub.3, .dbd.O, --OH, --OCH.sub.3, --OC(O)CH.sub.3, --NNH-2,4-Dinitrophenyl Hydrazine ("DNP"), and .dbd.S and [0009] R.sup.2 is selected from the group consisting of --H, --CH.sub.3, --CHO, --CH.sub.2OH, --CH.sub.2OCH.sub.3, --CH.sub.2OC(O)CH.sub.3, --COCH.sub.3, --COOH, and --CH.dbd.NNH-2,4-DNP, or a pharmaceutically acceptable salt or derivative thereof under conditions effective to treat the cancer. [0010] Another aspect of the present invention relates to a conjugated betulinol derivative monomer compound having the formula: where [0011] R.sub.1 is selected from the group consisting of --CH.sub.3, .dbd.O, --OH, --OCH.sub.3, --OC(O)CH.sub.3, --NNH-2,4-DNP, and .dbd.S; [0012] R.sub.3 is selected from the group consisting of H and C.sub.1-C.sub.5 alkyl; [0013] n is an integer from 1-12; and [0014] Z is H or a protective group or a pharmaceutically acceptable salt thereof. [0015] A further aspect of the present invention relates to a method of making a conjugated betulinol derivative monomer compound as described above. This method involves reacting a reactant compound of the formula with a betulinol derivative compound of the formula where [0016] R.sub.2 is a carbonyl containing group, under conditions effective to make the conjugated betulinol derivative monomer compound. [0017] Yet another aspect of the present invention relates to a conjugated betulinol derivative dimer compound having the formula where [0018] Y.sub.1 and Y.sub.2 are independently selected from the group consisting of --CH.sub.3, .dbd.O, --OH, --OCH.sub.3, --OC(O)CH.sub.3, --NNH-2,4-DNP, and .dbd.S; Continue reading about Betulinol derivatives as anti-cancer agents... Full patent description for Betulinol derivatives as anti-cancer agents Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Betulinol derivatives as anti-cancer agents patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Betulinol derivatives as anti-cancer agents or other areas of interest. ### Previous Patent Application: Shortening of hospital stay and improving survival in patients with chronic kidney disease Next Patent Application: Betulinol derivatives as anti-hiv agents Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Betulinol derivatives as anti-cancer agents patent info. IP-related news and info Results in 0.27674 seconds Other interesting Feshpatents.com categories: Qualcomm , Schering-Plough , Schlumberger , Seagate , Siemens , Texas Instruments , 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
